TNFRSF17 and Miyoshi myopathy: A “head to head” comparison of anti-BCMA targeted therapy will be difficult, but ongoing trials facing optimized response with manageable toxicity and the incorporation in earlier therapy lines will further improve the landscape of MM therapy.